Rockefeller Capital Management L.P. Sells 35,864 Shares of CRISPR Therapeutics AG $CRSP

Rockefeller Capital Management L.P. cut its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 24.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 112,667 shares of the company’s stock after selling 35,864 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in CRISPR Therapeutics were worth $5,908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of CRSP. Fund Advisors of America Inc FL bought a new position in CRISPR Therapeutics during the 4th quarter valued at about $398,000. Virtu Financial LLC bought a new stake in shares of CRISPR Therapeutics in the fourth quarter worth approximately $862,000. Mcguire Capital Advisors Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $25,000. Axxcess Wealth Management LLC raised its holdings in shares of CRISPR Therapeutics by 6.2% during the fourth quarter. Axxcess Wealth Management LLC now owns 13,022 shares of the company’s stock valued at $683,000 after purchasing an additional 764 shares during the last quarter. Finally, Corient Private Wealth LLC raised its holdings in shares of CRISPR Therapeutics by 5.7% during the fourth quarter. Corient Private Wealth LLC now owns 8,566 shares of the company’s stock valued at $449,000 after purchasing an additional 460 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Naimish Patel sold 3,786 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the sale, the insider directly owned 19,357 shares in the company, valued at $1,076,636.34. This represents a 16.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.30% of the stock is currently owned by insiders.

CRISPR Therapeutics Stock Performance

CRSP opened at $54.92 on Friday. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. The company has a market cap of $5.30 billion, a price-to-earnings ratio of -8.83 and a beta of 1.74. The company’s 50 day moving average is $52.72 and its 200 day moving average is $53.07. CRISPR Therapeutics AG has a 12-month low of $44.12 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The business had revenue of $1.46 million for the quarter. On average, equities research analysts predict that CRISPR Therapeutics AG will post -4.89 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Monday, April 20th. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research note on Thursday, June 11th. UBS Group set a $80.00 price target on CRISPR Therapeutics in a research note on Friday, June 12th. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Sanford C. Bernstein upped their price objective on CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $67.78.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.